These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16859587)

  • 1. What place for the new biologics in the treatment of necrotising vasculitides.
    Jayne D
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S1-5. PubMed ID: 16859587
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides.
    Guillevin L; Pagnoux C
    Isr Med Assoc J; 2008 Jan; 10(1):89-91. PubMed ID: 18300585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Part 2: Synopsis of B-lymphocyte targeted therapy of ANCA-associated vasculitis.
    Golbin JM; Specks U
    Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S74-6. PubMed ID: 17428376
    [No Abstract]   [Full Text] [Related]  

  • 4. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Part 3: Newer therapies for ANCA-associated vasculitis.
    Jayne D
    Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S77-9. PubMed ID: 17428377
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on the use of biologics in vasculitides.
    Vishwanath S; Relan M; Shen L; Ambrus JL
    Curr Pharm Biotechnol; 2014; 15(6):558-62. PubMed ID: 25213365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies for systemic necrotizing vasculitides.
    Guillevin L; Pagnoux C
    Allergol Int; 2007 Jun; 56(2):105-11. PubMed ID: 17460440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biotherapies to treat necrotizing vasculitis].
    Guillevin L
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S304-6. PubMed ID: 21055849
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological drugs in ANCA-associated vasculitis.
    Lutalo PM; D'Cruz DP
    Int Immunopharmacol; 2015 Aug; 27(2):209-12. PubMed ID: 25907243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy.
    Quartuccio L; Isola M; Masolini P; Scaini P; Zani R; Tavoni A; Pietrogrande M; Bombardieri S; De Vita S
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S9-14. PubMed ID: 23044040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
    Flossmann O; Jones RB; Jayne DR; Luqmani RA
    Ann Rheum Dis; 2006 Jul; 65(7):841-4. PubMed ID: 16769779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic vasculitis treatment and monitoring update, 2008.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2008; 66(3):228-30. PubMed ID: 18937637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics in dermatology: adverse effects.
    Sehgal VN; Pandhi D; Khurana A
    Int J Dermatol; 2015 Dec; 54(12):1442-60. PubMed ID: 26147909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin.
    Jayne DR; Esnault VL; Lockwood CM
    J Autoimmun; 1993 Apr; 6(2):207-19. PubMed ID: 8499059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New strategies in the treatment of systemic vasculitis.
    Jayne DR; Lockwood CM
    Ann Med Interne (Paris); 1994; 145(8):595-600. PubMed ID: 7710186
    [No Abstract]   [Full Text] [Related]  

  • 17. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
    Holle JU; Gross WL
    J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks?
    Korkina L; Trakhtman P; De Luca C; Leoni L; Raskovic D; Pastore S
    Drugs Today (Barc); 2010 Feb; 46(2):119-36. PubMed ID: 20393640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Remissions in Recalcitrant Pemphigus Vulgaris.
    Ahmed AR; Kaveri S; Spigelman Z
    N Engl J Med; 2015 Dec; 373(27):2693-4. PubMed ID: 26716930
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary systemic vasculitis.
    Day C; Savage C
    Minerva Med; 2001 Oct; 92(5):349-63. PubMed ID: 11675579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.